Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement prod… Read more
Edwards Lifesciences Corp (EW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.056x
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has a cash flow conversion efficiency ratio of 0.056x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($573.70 Million) by net assets ($10.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Edwards Lifesciences Corp - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Edwards Lifesciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Edwards Lifesciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edwards Lifesciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carrier Global Corp
NYSE:CARR
|
0.072x |
|
Electronic Arts Inc
NASDAQ:EA
|
0.297x |
|
Malayan Banking Berhad
PINK:MLYBY
|
-0.080x |
|
Public Storage
NYSE:PSA
|
0.079x |
|
Chipotle Mexican Grill Inc
NYSE:CMG
|
0.150x |
|
China Hongqiao Group Limited
PINK:CHHQY
|
0.192x |
|
Yum! Brands Inc
NYSE:YUM
|
-0.084x |
|
APOLLO GL.M.NEW DL-00001
F:N7I
|
N/A |
Annual Cash Flow Conversion Efficiency for Edwards Lifesciences Corp (1999–2024)
The table below shows the annual cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.06 Billion | $542.30 Million | 0.054x | -59.58% |
| 2023-12-31 | $6.72 Billion | $895.80 Million | 0.133x | -36.45% |
| 2022-12-31 | $5.81 Billion | $1.22 Billion | 0.210x | -29.32% |
| 2021-12-31 | $5.84 Billion | $1.73 Billion | 0.297x | +28.77% |
| 2020-12-31 | $4.57 Billion | $1.05 Billion | 0.230x | -18.93% |
| 2019-12-31 | $4.15 Billion | $1.18 Billion | 0.284x | -3.66% |
| 2018-12-31 | $3.14 Billion | $926.80 Million | 0.295x | -11.68% |
| 2017-12-31 | $2.99 Billion | $1.00 Billion | 0.334x | +24.24% |
| 2016-12-31 | $2.62 Billion | $704.40 Million | 0.269x | +22.47% |
| 2015-12-31 | $2.50 Billion | $549.70 Million | 0.220x | -52.92% |
| 2014-12-31 | $2.19 Billion | $1.02 Billion | 0.467x | +53.88% |
| 2013-12-31 | $1.56 Billion | $472.70 Million | 0.303x | +19.98% |
| 2012-12-31 | $1.48 Billion | $373.80 Million | 0.253x | +7.49% |
| 2011-12-31 | $1.34 Billion | $314.50 Million | 0.235x | +22.32% |
| 2010-12-31 | $1.31 Billion | $251.40 Million | 0.192x | +34.61% |
| 2009-12-31 | $1.16 Billion | $165.30 Million | 0.143x | -18.11% |
| 2008-12-31 | $878.80 Million | $153.20 Million | 0.174x | -30.75% |
| 2007-12-31 | $835.00 Million | $210.20 Million | 0.252x | -18.26% |
| 2006-12-31 | $749.40 Million | $230.80 Million | 0.308x | +55.34% |
| 2005-12-31 | $690.00 Million | $136.80 Million | 0.198x | -31.05% |
| 2004-12-31 | $628.10 Million | $180.60 Million | 0.288x | +49.32% |
| 2003-12-31 | $635.10 Million | $122.30 Million | 0.193x | -13.87% |
| 2002-12-31 | $539.40 Million | $120.60 Million | 0.224x | +1.61% |
| 2001-12-31 | $459.00 Million | $101.00 Million | 0.220x | -29.33% |
| 2000-12-31 | $440.00 Million | $137.00 Million | 0.311x | +116.54% |
| 1999-12-31 | $1.22 Billion | $176.00 Million | 0.144x | -- |